Acute Lymphoblastic Leukemia with Kmt2a Rearrangements

• FDA approval · 2024-11-15
  FDA Approved: REVUFORJ — Original Application (Syndax Pharmaceuticals, Inc.)

  FDA approves REVUFORJ (revumenib) from Syndax for patients with acute leukemias that harbor KMT2A gene rearrangements, in relapsed or refrac…